364 related articles for article (PubMed ID: 20068564)
21. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade.
Niyazi M; Marini P; Daniel PT; Humphreys R; Jendrossek V; Belka C
Strahlenther Onkol; 2009 Jan; 185(1):8-18. PubMed ID: 19224142
[TBL] [Abstract][Full Text] [Related]
23. Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1.
Moretto P; Hotte SJ
Expert Opin Investig Drugs; 2009 Mar; 18(3):311-25. PubMed ID: 19243282
[TBL] [Abstract][Full Text] [Related]
24. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells.
Ahmed SM; Wu X; Jin X; Zhang X; Togo Y; Suzuki T; Li Y; Kanematsu A; Nojima M; Yamamoto S; Sugimoto M; Kakehi Y
Oncol Rep; 2015 Feb; 33(2):566-72. PubMed ID: 25483927
[TBL] [Abstract][Full Text] [Related]
25. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.
Plummer R; Attard G; Pacey S; Li L; Razak A; Perrett R; Barrett M; Judson I; Kaye S; Fox NL; Halpern W; Corey A; Calvert H; de Bono J
Clin Cancer Res; 2007 Oct; 13(20):6187-94. PubMed ID: 17947486
[TBL] [Abstract][Full Text] [Related]
28. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
[TBL] [Abstract][Full Text] [Related]
29. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
[TBL] [Abstract][Full Text] [Related]
30. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
31. Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis.
Zhang X; Frank AC; Gille CM; Daucher M; Kabat J; Becker S; Lempicki RA; Cortez KJ; Polis MA; Subramanian GM; Kottilil S
Hepatol Res; 2009 Dec; 39(12):1178-89. PubMed ID: 19788693
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
Chung KY; Gore I; Fong L; Venook A; Beck SB; Dorazio P; Criscitiello PJ; Healey DI; Huang B; Gomez-Navarro J; Saltz LB
J Clin Oncol; 2010 Jul; 28(21):3485-90. PubMed ID: 20498386
[TBL] [Abstract][Full Text] [Related]
33. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
Gong J; Yang D; Kohanim S; Humphreys R; Broemeling L; Kurzrock R
Mol Cancer Ther; 2006 Dec; 5(12):2991-3000. PubMed ID: 17148761
[TBL] [Abstract][Full Text] [Related]
34. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
Younes M; Georgakis GV; Rahmani M; Beer D; Younes A
Eur J Cancer; 2006 Mar; 42(4):542-7. PubMed ID: 16426839
[TBL] [Abstract][Full Text] [Related]
35. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).
Forero-Torres A; Shah J; Wood T; Posey J; Carlisle R; Copigneaux C; Luo FR; Wojtowicz-Praga S; Percent I; Saleh M
Cancer Biother Radiopharm; 2010 Feb; 25(1):13-9. PubMed ID: 20187792
[TBL] [Abstract][Full Text] [Related]
37. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
[TBL] [Abstract][Full Text] [Related]
38. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.
Infante JR; Bendell JC; Goff LW; Jones SF; Chan E; Sudo T; Burris HA; Berlin JD
Eur J Cancer; 2013 Apr; 49(6):1169-75. PubMed ID: 23294608
[TBL] [Abstract][Full Text] [Related]
39. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C
Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
